Amgen Inc
NASDAQ:AMGN

Watchlist Manager
Amgen Inc Logo
Amgen Inc
NASDAQ:AMGN
Watchlist
Price: 294.53 USD 1.6% Market Closed
Market Cap: 158.3B USD
Have any thoughts about
Amgen Inc?
Write Note

Amgen Inc
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Amgen Inc
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Amgen Inc
NASDAQ:AMGN
Other Liabilities
$4.5B
CAGR 3-Years
-20%
CAGR 5-Years
-14%
CAGR 10-Years
-4%
Abbvie Inc
NYSE:ABBV
Other Liabilities
$33B
CAGR 3-Years
4%
CAGR 5-Years
16%
CAGR 10-Years
28%
Gilead Sciences Inc
NASDAQ:GILD
Other Liabilities
$24.4B
CAGR 3-Years
63%
CAGR 5-Years
29%
CAGR 10-Years
39%
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Other Liabilities
$1.9B
CAGR 3-Years
5%
CAGR 5-Years
27%
CAGR 10-Years
54%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Liabilities
$2.5B
CAGR 3-Years
56%
CAGR 5-Years
50%
CAGR 10-Years
44%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Liabilities
$1.8B
CAGR 3-Years
35%
CAGR 5-Years
13%
CAGR 10-Years
23%
No Stocks Found

Amgen Inc
Glance View

Market Cap
158.3B USD
Industry
Biotechnology

Amgen Inc., a leader in the biopharmaceutical industry, has spent over four decades revolutionizing the way we approach complex diseases. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen harnesses the power of human biology to develop innovative therapies for serious illnesses. Its robust portfolio features groundbreaking products that target diseases such as cancer, kidney disease, and rheumatoid arthritis. Notably, Amgen's flagship drugs, like Enbrel and Neulasta, have garnered significant market presence, contributing to the company’s solid financial performance. The firm’s commitment to research and development is underscored by its considerable investments in biotechnology, yielding a promising pipeline of future treatments that aim to improve patient lives while also providing strong returns for investors. As a powerhouse in the healthcare sector, Amgen stands out not just for its scientific advancements, but also for its strategic approach to growth. The company has embraced a culture of continuous improvement and collaboration, forming partnerships that enhance its market reach and innovation potential. With a focus on sustainable practices, Amgen is dedicated to ensuring that its operations are environmentally responsible while also delivering durable financial results. Its steady revenue growth and focus on shareholder return further bolster its profile as an attractive investment option. As healthcare demands evolve and an increasing global population seeks better treatments, Amgen is well-positioned to capitalize on these opportunities, making it a compelling choice for investors looking to navigate the dynamic biotech landscape.

AMGN Intrinsic Value
252.91 USD
Overvaluation 14%
Intrinsic Value
Price

See Also

What is Amgen Inc's Other Liabilities?
Other Liabilities
4.5B USD

Based on the financial report for Sep 30, 2024, Amgen Inc's Other Liabilities amounts to 4.5B USD.

What is Amgen Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
-4%

Over the last year, the Other Liabilities growth was -35%. The average annual Other Liabilities growth rates for Amgen Inc have been -20% over the past three years , -14% over the past five years , and -4% over the past ten years .

Back to Top